ClinicalTrials.gg
CompletedNCT02480894Updated Sep 25, 2017

A Open-label, Drug-Drug Interaction With Maraviroc (DDI)

A Phase 1 interventional study of BMS-663068 and Maraviroc in Infection, Human Immunodeficiency Virus, sponsored by ViiV Healthcare. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-09-25.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
112
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This is a Phase 1, open-label, single sequence, two-way interaction study in healthy male and female subjects. For the effect of maraviroc on the pharmacokinetics (PK) of BMS-626529 (the active moiety of BMS-663068), there is no formal hypothesis to be statistically tested. The purpose of this assessment is to estimate the effect of maraviroc on the PK of BMS-626529 when coadministered in healthy subjects. For the effect of BMS-663068 on the PK of maraviroc, the hypothesis to be statistically tested is that BMS-663068 will not have a clinically significant effect on the PK of maraviroc when coadministered in healthy subjects.

02

Conditions studied

  • Infection, Human Immunodeficiency Virus
03

In context

Infections

2,096 studies on the registry are indexed under Infections; 364 are open to participants now.

This study's enrollment of 112 is close to the median of 113 across 1,304 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female nonsmoking subjects ages 18 to 50 years, inclusive with a of 18.0 to 32.0 kg/m2, inclusive
  • Women of must agree to follow instructions for methods of for a total of 34 days post-treatment completion

Exclusion criteria

Exclusion Criteria:

  • Any condition possibly affecting drug absorption
  • Pre-existing liver dysfunction
  • Any significant acute or chronic medical illness
  • Orthostatic intolerance
  • Other protocol specified exclusion criteria could apply
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
112 participants (actual)

Study arms

  • Experimental
    Sequential Dosing

    Treatment A: BMS-663068 orally twice daily (BID) on Days 1 through 4 Treatment B: Maraviroc BID on Days 7 through 11 Treatment C: BMS-663068 BID plus maraviroc BID on Days 12 through 18

    Drug: BMS-663068 · Drug: Maraviroc

Interventions

06

What researchers measure

Primary outcomes

  1. BMS-626529 Pharmacokinetics: maximum observed plasma concentration (Cmax)

    PK parameters for BMS-626529 in the absence or presence of multiple doses of maraviroc include: - Cmax

    Time frame: predose and up to 12 hours post dose on Days 4, 16, 17, and 18

  2. BMS-626529 Pharmacokinetics: area under the plasma concentration-time curve (AUC) in a single dosing interval AUC(TAU)

    PK parameters for BMS-626529 in the absence or presence of multiple doses of maraviroc include: - AUC(TAU)

    Time frame: predose and up to 12 hours post dose on Days 4, 16, 17, and 18

  3. Maraviroc Pharmacokinetics: Cmax

    PK parameters for maraviroc in the absence or presence of BMS-663068 include: - Cmax

    Time frame: predose and up to 12 hours post dose on Days 9, 10, 11, 16, 17, and 18

  4. Maraviroc Pharmacokinetics: AUC(TAU)

    PK parameters for maraviroc in the absence or presence of BMS-663068 include: - AUC(TAU)

    Time frame: predose and up to 12 hours post dose on Days 9, 10, 11, 16, 17, and 18

Secondary outcomes

  1. Other PK Parameters for BMS-626529: Time of maximum observed plasma concentration (Tmax)

    PK parameters for BMS-626529 include: - Tmax

    Time frame: predose and up to 12 hours post dose on Days 4, 16, 17, and 18

  2. Other PK Parameters for BMS-626529: plasma concentration observed at 12 hours post-dose (C12)

    PK parameters for BMS-626529 include: - C12

    Time frame: predose and up to 12 hours post dose on Days 4, 16, 17, and 18

  3. Other PK Parameters for BMS-626529: trough observed plasma concentration (Ctrough) (predose)

    PK parameters for BMS-626529 include: - Ctrough (predose)

    Time frame: predose and up to 12 hours post dose on Days 4, 16, 17, and 18

  4. Other PK Parameters for maraviroc: Tmax

    PK Parameters for maraviroc include: -Tmax

    Time frame: predose and up to 12 hours post dose on Days 9, 10, 11, 16, 17, and 18

  5. Other PK Parameters for maraviroc: C12

    PK Parameters for maraviroc include: * C12

    Time frame: predose and up to 12 hours post dose on Days 9, 10, 11, 16, 17, and 18

  6. Other PK Parameters for maraviroc: Ctrough

    PK Parameters for maraviroc include: - Ctrough

    Time frame: predose and up to 12 hours post dose on Days 9, 10, 11, 16, 17, and 18

  7. Clinical Safety as Measured by Adverse Events

    Adverse event monitoring

    Time frame: Day 1 to Day 26

  8. Clinical Safety as Measured by Vital Signs

    Vital sign measurement

    Time frame: Day 1 to Day 26

  9. Clinical Safety as Measured by Electrocardiograms (ECGs)

    12-lead ECGs

    Time frame: Day 1 to Day 26

  10. Clinical Safety as Measured by Physical Examination

    Physical examinations

    Time frame: Day 1 to Day 26

  11. Clinical Safety as Measured by Clinical Laboratory Evaluations

    Clinical chemistry, hematology, urinalysis

    Time frame: Day 1 to Day 26

07

Study locations

1 site
  • GSK Investigational Site
    San Antonio, Texas 78209, United States
08

References and documents

Publications

  • Wire MB, Magee M, Ackerman P, Llamoso C, Moore K. Evaluation of the pharmacokinetic drug-drug interaction between the antiretroviral agents fostemsavir and maraviroc: a single-sequence crossover study in healthy participants. HIV Res Clin Pract. 2021 Dec 9;23(1):1-8. Epub 2022 Mar 14. PubMed 35285786 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in Sep 2015, 2 months.

Of 51 industry-sponsored phase 1 interventional studies under Infections, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 13. This study's 2 months is below that.

Counting every sponsor, half of 78 studies reached it within 10 months; a quarter within 3 and three quarters within 20.

Infections covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2015
First posted
Jun 25, 2015
StartActual
Jul 7, 2015
Primary completionActual
Sep 21, 2015
CompletionActual
Sep 21, 2015
Last update
Sep 25, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02480894
Lead sponsor
ViiV Healthcare
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 25, 2015
Start date
Jul 7, 2015
Primary completion
Sep 21, 2015
Completion
Sep 21, 2015
Last update
Sep 25, 2017

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fostemsavir · Maraviroc

Start the discussion